Patents by Inventor Scott E. Gygax
Scott E. Gygax has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10829826Abstract: The present invention is based on the discovery of novel polymorphisms (SNPs) in the penicillin binding protein (pbp3) gene in Staphylococcus aureus. The presence of G88A and/or G2047A SNPs provides an accurate, reliable biomarker for the presence of Methicillin Resistant Staphylococcus aureus (MRSA), specifically the community-associated MRSA (CA-MRSA). The present invention provides reagents used for detecting the SNPs as well as methods of identifying and using these variants to screen subjects for presence of CA-MRSA. The methods involve isolating a biological sample from a mammal (preferably a human) and testing for the presence of a SNP in the pbp3 gene which is associated with CA-MRSA.Type: GrantFiled: February 21, 2019Date of Patent: November 10, 2020Inventors: Scott E. Gygax, Sean Chadwick, Aditya Prasad, Martin E. Adelson, Eli Mordechai
-
Publication number: 20190177772Abstract: The present invention is based on the discovery of novel polymorphisms (SNPs) in the penicillin binding protein (pbp3) gene in Staphylococcus aureus. The presence of G88A and/or G2047A SNPs provides an accurate, reliable biomarker for the presence of Methicillin Resistant Staphylococcus aureus (MRSA), specifically the community-associated MRSA (CA-MRSA). The present invention provides reagents used for detecting the SNPs as well as methods of identifying and using these variants to screen subjects for presence of CA-MRSA. The methods involve isolating a biological sample from a mammal (preferably a human) and testing for the presence of a SNP in the pbp3 gene which is associated with CA-MRSA.Type: ApplicationFiled: February 21, 2019Publication date: June 13, 2019Applicant: Medical Diagnostic Laboratories, LLCInventors: Scott E. Gygax, Sean Chadwick, Aditya Prasad, Martin E. Adelson, Eli Mordechai
-
Patent number: 10221462Abstract: The present invention is based on the discovery of polymorphisms (SNPs) in the penicillin binding protein (pbp3) gene in Staphylococcus aureus. The presence of G88A and/or G2047A SNPs provides an accurate, reliable biomarker for the presence of Methicillin Resistant Staphylococcus aureus (MRSA), specifically the community-associated MRSA (CA-MRSA). The present invention provides reagents used for detecting the SNPs as well as methods of identifying and using these variants to screen subjects for presence of CA-MRSA. The methods involve isolating a biological sample from a mammal (preferably a human) and testing for the presence of a SNP in the pbp3 gene which is associated with CA-MRSA.Type: GrantFiled: July 14, 2017Date of Patent: March 5, 2019Assignee: Medical Diagnostic Laboratories, LLC.Inventors: Scott E. Gygax, Sean Chadwick, Aditya Prasad, Martin E. Adelson, Eli Mordechai
-
Publication number: 20170314065Abstract: The present invention is based on the discovery of novel polymorphisms (SNPs) in the penicillin binding protein (pbp3) gene in Staphylococcus aureus. The presence of G88A and/or G2047A SNPs provides an accurate, reliable biomarker for the presence of Methicillin Resistant Staphylococcus aureus (MRSA), specifically the community-associated MRSA (CA-MRSA). The present invention provides reagents used for detecting the SNPs as well as methods of identifying and using these variants to screen subjects for presence of CA-MRSA. The methods involve isolating a biological sample from a mammal (preferably a human) and testing for the presence of a SNP in the pbp3 gene which is associated with CA-MRSA.Type: ApplicationFiled: July 14, 2017Publication date: November 2, 2017Applicant: Medical Diagnostic Laboratories, LLCInventors: Scott E. Gygax, Sean Chadwick, Aditya Prasad, Martin E. Adelson, Eli Mordechai
-
Publication number: 20170260570Abstract: The present invention relates to an antibiotic resistance profile for Neisseria gonorrhoeae by assessing the presence of mutations (e.g., SNP) in antibiotic resistant genes that confer bacterial resistance against antibiotics such as penicillin, tetracycline, fluoroquinolones, cephalosporin, macrolides and spectinomycin. There is provided a method and a kit for generating an antibiotic resistance profile for Neisseria gonorrhoeae by utilizing a multiplex PCR to amplify segments of antibiotic-resistant genes, allele-specific primer extension to detect gene mutation, and detection of such gene mutations with gel electrophoresis, capillary electrophoresis, or DNA microarray. The present method provides useful information to physicians relating the antibiotic susceptibility of Neisseria gonorrhoeae against different classes of antibiotics.Type: ApplicationFiled: March 11, 2016Publication date: September 14, 2017Inventors: Sergey Balashov, Eli Mordechai, Martin E. Adelson, Scott E. Gygax
-
Patent number: 9738938Abstract: The present invention is based on the discovery of polymorphisms (SNPs) in the penicillin binding protein (pbp3) gene in Staphylococcus aureus. The presence of G88A and/or G2047A SNPs provides an accurate, reliable biomarker for the presence of Methicillin Resistant Staphylococcus aureus (MRSA), specifically the community-associated MRSA (CA-MRSA). The present invention provides reagents used for detecting the SNPs as well as methods of identifying and using these variants to screen subjects for presence of CA-MRSA. The methods involve isolating a biological sample from a mammal (preferably a human) and testing for the presence of a SNP in the pbp3 gene which is associated with CA-MRSA.Type: GrantFiled: May 9, 2011Date of Patent: August 22, 2017Assignee: Medical Diagnostic Laboratories, LLCInventors: Scott E. Gygax, Sean Chadwick, Aditya Prasad, Martin E. Adelson, Eli Mordechai
-
Patent number: 9593384Abstract: The present invention is directed to the discovery of single nucleotide polymorphisms (SNPs) in the presence of metronidazole-resistant Trichomonas vaginalis. The presence of G76C, C213G, or C318A (SNP) in tvntr 4 or the presence of A238T, G427C, or T476C (SNP) in tvntr6 provides a reliable biomarker for the presence of metronidazole-resistant Trichomonas vaginalis. The present invention further provides reagents used for detecting the SNPs to screen subjects for metronidazole resistance in Trichomonas vaginalis.Type: GrantFiled: April 22, 2014Date of Patent: March 14, 2017Assignee: Medical Diagnostic Laboratories, LLCInventors: David W Hilbert, Scott E Gygax, Martin E. Adelson, Eli Mordechai, Jessica Schuyler, Teresa Paulish-Miller
-
Patent number: 9297048Abstract: The present invention relates to an antibiotic resistance profile for Neisseria gonorrhoeae by assessing the presence of mutations (e.g., SNP) in antibiotic resistant genes that confer bacterial resistance against antibiotics such as penicillin, tetracycline, fluoroquinolones, cephalosporin, macrolides and spectinomycin. There is provided a method and a kit for generating an antibiotic resistance profile for Neisseria gonorrhoeae by utilizing a multiplex PCR to amplify segments of antibiotic-resistant genes, allele-specific primer extension to detect gene mutation, and detection of such gene mutations with gel electrophoresis, capillary electrophoresis, or DNA microarray. The present method provides useful information to physicians relating the antibiotic susceptibility of Neisseria gonorrhoeae against different classes of antibiotics.Type: GrantFiled: June 2, 2011Date of Patent: March 29, 2016Assignee: Medical Diagnostic Laboratories, LLCInventors: Sergey Balashov, Eli Mordechai, Martin E. Adelson, Scott E. Gygax
-
Publication number: 20140377749Abstract: The present invention is directed to the discovery of single nucleotide polymorphisms (SNPs) in the presence of metronidazole-resistant Trichomonas vaginalis. The presence of G76C, C213G, or C318A (SNP) in tvntr 4 or the presence of A238T, G427C, or T476C (SNP) in tvntr6 provides a reliable biomarker for the presence of metronidazole-resistant Trichomonas vaginalis. The present invention further provides reagents used for detecting the SNPs to screen subjects for metronidazole resistance in Trichomonas vaginalis.Type: ApplicationFiled: April 22, 2014Publication date: December 25, 2014Applicant: MEDICAL DIAGNOSTIC LABORATORIES, LLCInventors: David W. Hilbert, Scott E. Gygax, Martin E. Adelson, Eli Mordechai, Jessica Schuyler, Teresa Paulish-Miller
-
Patent number: 8741563Abstract: The present invention is directed to the discovery of single nucleotide polymorphisms (SNPs) in the presence of metronidazole-resistant Trichomonas vaginalis. The presence of G76C, C213G, or C318A (SNP) in tvntr 4 or the presence of A238T, G427C, or T476C (SNP) in tvntr6 provides a reliable biomarker for the presence of metronidazole-resistant Trichomonas vaginalis. The present invention further provides reagents used for detecting the SNPs to screen subjects for metronidazole resistance in Trichomonas vaginalis.Type: GrantFiled: November 19, 2012Date of Patent: June 3, 2014Assignee: Medical Diagnostic Laboratories, LLCInventors: David W. Hilbert, Scott E. Gygax, Martin E. Adelson, Eli Mordechai, Jessica Schuyler, Teresa Paulish-Miller
-
Patent number: 8715936Abstract: Disclosed are diagnostic methods for determining a subtype of methicillin-resistant Staphylococcus aureus (MRSA) in a biological sample of a mammal. Methods include providing a biological sample of the mammal, performing a PCR analysis of the biological sample, and analyzing the PCR amplicons with respect to their sizes so as to determine for type I, type II, type III, type IV or type V MRSA that may be present in the biological sample. Further example embodiments include using at least one mecA primer pair and/or using at least one Staphylococcus aureus nuc primer pair in the PCR analysis. Further disclosed are methods for screening populations for MRSA, and methods of treating a mammal testing positive for Type IV MRSA. Also disclosed are kits for determining a MRSA subtype in a mammal and isolated primers that may be used in the present methods and kits.Type: GrantFiled: January 13, 2011Date of Patent: May 6, 2014Assignee: Medical Diagnostic Laboratories, LLCInventors: Scott E. Gygax, Christina Lim Overmyer, Lisa A. DeSalvia, Martin E. Adelson, Eli Mordechai
-
Publication number: 20120071336Abstract: The present invention relates to an antibiotic resistance profile for Neisseria gonorrhoeae by assessing the presence of mutations (e.g., SNP) in antibiotic resistant genes that confer bacterial resistance against antibiotics such as penicillin, tetracycline, fluoroquinolones, cephalosporin, macrolides and spectinomycin. There is provided a method and a kit for generating an antibiotic resistance profile for Neisseria gonorrhoeae by utilizing a multiplex PCR to amplify segments of antibiotic-resistant genes, allele-specific primer extension to detect gene mutation, and detection of such gene mutations with gel electrophoresis, capillary electrophoresis, or DNA microarray. The present method provides useful information to physicians relating the antibiotic susceptibility of Neisseria gonorrhoeae against different classes of antibiotics.Type: ApplicationFiled: June 2, 2011Publication date: March 22, 2012Applicant: Medical Diagnostic Laboratories, LLCInventors: Sergey Balashov, Eli Mordechai, Martin E. Adelson, Scott E. Gygax
-
Publication number: 20120009572Abstract: The present invention is based on the discovery of novel polymorphisms (SNPs) in the penicillin binding protein (pbp3) gene in Staphylococcus aureus. The presence of G88A and/or G2047A SNPs provides an accurate, reliable biomarker for the presence of Methicillin Resistant Staphylococcus aureus (MRSA), specifically the community-associated MRSA (CA-MRSA). The present invention provides reagents used for detecting the SNPs as well as methods of identifying and using these variants to screen subjects for presence of CA-MRSA. The methods involve isolating a biological sample from a mammal (preferably a human) and testing for the presence of a SNP in the pbp3 gene which is associated with CA-MRSA.Type: ApplicationFiled: May 9, 2011Publication date: January 12, 2012Applicant: Medical Diagnostic Laboratories, LLCInventors: Scott E. Gygax, Sean Chadwick, Aditya Prasad, Martin E. Adelson, Eli Mordechai
-
Patent number: 8021846Abstract: There is disclosed a method for determining azole resistance in Candida glabrata. A biological sample containing Candida glabrata is obtained and a normalized mRNA level of CDR1 gene is determined using qRT-PCR. Using a microbroth dilution assay conducted at azole concentrations of about 2-8 ?g/mL, a susceptible isolate of Candida glabrata is obtained. A qRT-PCR assay is employed on the susceptible isolate and an average mRNA level of CDR1 is obtained. A fold-change value for CDR1 is obtained by comparing the CDR1 mRNA level of the biological sample with that of the average mRNA level. A ?2-fold change value is indicative of an azole resistance in Candida glabrata. The present method provides a qRT-PCR assay for azole resistance that has a sensitivity of ?90% and a specificity of ?90%.Type: GrantFiled: March 12, 2009Date of Patent: September 20, 2011Assignee: Medical Diagnostic Laboratories, LLCInventors: Scott E. Gygax, John-Paul Vermitsky, Sean G. Chadwick, Matthew J. Self, Eli Mordechai, Martin E. Adelson
-
Publication number: 20090305274Abstract: There is disclosed a method for determining azole resistance in Candida glabrata. A biological sample containing Candida glabrata is obtained and a normalized mRNA level of CDR1 gene is determined using qRT-PCR. Using a microbroth dilution assay conducted at azole concentrations of about 2-8 ?g/mL, a susceptible isolate of Candida glabrata is obtained. A qRT-PCR assay is employed on the susceptible isolate and an average mRNA level of CDR1 is obtained. A fold-change value for CDR1 is obtained by comparing the CDR1 mRNA level of the biological sample with that of the average mRNA level. A ?2-fold change value is indicative of an azole resistance in Candida glabrata. The present method provides a qRT-PCR assay for azole resistance that has a sensitivity of ?90% and a specificity of ?90%.Type: ApplicationFiled: March 12, 2009Publication date: December 10, 2009Applicant: Medical Diagnostic Laboratories, LLCInventors: Scott E. Gygax, John-Paul Vermitsky, Sean G. Chadwick, Matthew J. Self, Eli Mordechai, Martin E. Adelson